Sanofi $SNY Stock: Quadrant Capital Group LLC Trims Position

Quadrant Capital Group LLC lowered its stake in shares of Sanofi (NASDAQ:SNY) by 81.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,607 shares of the company’s stock after selling 33,376 shares during the period. Quadrant Capital Group LLC’s holdings in Sanofi were worth $298,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cohen Investment Advisors LLC lifted its holdings in Sanofi by 4.8% in the 3rd quarter. Cohen Investment Advisors LLC now owns 11,600 shares of the company’s stock valued at $478,000 after purchasing an additional 536 shares in the last quarter. Net Worth Advisory Group acquired a new stake in shares of Sanofi during the 3rd quarter worth about $296,000. Focused Alpha LLC boosted its stake in shares of Sanofi by 4.5% during the 3rd quarter. Focused Alpha LLC now owns 6,553 shares of the company’s stock worth $270,000 after purchasing an additional 281 shares during the last quarter. CWA Asset Management Group LLC grew its holdings in shares of Sanofi by 12.3% during the third quarter. CWA Asset Management Group LLC now owns 65,656 shares of the company’s stock worth $2,707,000 after buying an additional 7,181 shares in the last quarter. Finally, First Bank & Trust grew its holdings in shares of Sanofi by 16.2% during the third quarter. First Bank & Trust now owns 97,494 shares of the company’s stock worth $4,020,000 after buying an additional 13,561 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SNY shares. Wall Street Zen downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Weiss Ratings upgraded shares of Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. HSBC reiterated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Stock Up 0.5%

Shares of NASDAQ:SNY opened at $41.79 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68. The stock has a market capitalization of $101.32 billion, a P/E ratio of 21.88, a PEG ratio of 1.28 and a beta of 0.33. The stock has a 50-day simple moving average of $42.38 and a 200-day simple moving average of $44.46.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.24 EPS. Equities analysts forecast that Sanofi will post 5.00 earnings per share for the current year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.